Originally published by Elsevier Journals on 24 May 2011, this white paper outlines an open-label, randomised, single-dose, parallel-group study of the pharmacokinetics of oral cyanocobalamin formulated with Sodium N-[8-(2-hydroxy benzoyl) amino] caprylate (SNAC).
Vitamin B12 deficiency may be caused by inadequate dietary intake or by conditions that result in malabsorption. Usually in the form of cyanocobalamin, crystalline vitamin B12 is administered parenterally or orally for the treatment of deficiency states.
Intramuscular administration is widely accepted as a treatment method and oral B12 supplements are also used but are considered less reliable.
More About This Company
Development Update
Novo Nordisk announced the European Commission (EC) has granted marketing authorisation for Rybelsus®, (oral semaglutide),...
Emisphere Development Update
Novo Nordisk has announced the Federal Food and Drug Administration (FDA) approved Rybelsus, a semaglutide...
Study: Comparing Efficacy and Tolerability of New Daily Oral Vitamin B12 and Intermittent Intramuscular Vitamin B12
This study was originally published by Elsevier HS Journals on March 14, 2011. The objective...